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a b s t r a c t
The response to DNA damage by alkylation and DNA topoisomerase inhibition was stud-
ied in two breast cancer cells lines. We present data from both a shotgun and a targeted,
pathway-centric approach to highlight the different DNA repair pathway modulation in the
cell lines and the correlation with viability and DNA damage assays. This type of focussed
proﬁling may be of utility in rapidly deﬁning non-responders undergoing systemic neoad-
juvant therapy.
© 2015 The Authors. Published by Elsevier B.V. on behalf of European Proteomics
Association (EuPA). This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Each cell in the body is constantly exposed to DNA damaging
agents, such as UV light or industrial chemicals, generating
thousands of lesions a day in cellular DNA. In order to secure
the accurate passing of genetic information to the next gen-
eration, the cell has evolved an intricate surveillance system
to ﬁnd and correct this damage. This surveillance system
Abbreviations: MMR, mismatch repair; dNTP, deoxynucleotide triphosphate; BER, base excision repair; DSB, double strand break; HR,
homologous recombination; NEHJ, non-homologous end-joining; NER, nucleotide excision repair; DDR, DNA damage repair; DDS, DNA
damage signalling; MMS, methyl methanesulphonate; DR, doxorubicin.
∗ Corresponding author at: Department of Immunotechnology, House 406 Medicon Village, 223 81 Lund, Sweden. Tel.: +46 46 222 1496.
E-mail address: peter.james@immun.lth.se (P. James).
consists of several cell-cycle checkpoints, which ensure DNA
repair occurs before replication of the DNA and cell division.
The main DNA repair pathways are: mismatch repair (MMR)
detects and deals with dNTP misincorporation and inser-
tions/deletions; nucleotide excision repair (NER) recognise
helix-distorting base lesions from, for example UV damage
while oxidative lesions and alkylation products are repaired
through base excision repair (BER) and there are two dif-
ferent mechanisms dealing with double strand breaks (DSB)
http://dx.doi.org/10.1016/j.euprot.2015.05.002
2212-9685/© 2015 The Authors. Published by Elsevier B.V. on behalf of European Proteomics Association (EuPA). This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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[1]. These are homologous recombination (HRR) which is
restricted to S and G2 phase since it is using sister-chromatid
sequences as templates [2] and the more error-prone (NHEJ)
that is occurring throughout the cell cycle [3–6].
Cancer cells often increase the rate ofmutationduring their
development in order to enable the acquisition of the other
cancer hallmarks. This is achieved by disabling one or more
components of the DNA damage surveillance system [7]. As a
consequence, mutations in various DNA repair pathways are
commonly seen in different cancers, e.g. BRCA1 and 2 muta-
tions giving rise to an aberrant HRR are found in more than
50% of patients with hereditary breast cancer and hereditary
defects in NER cause UV sensitivity and skin cancer devel-
opment [8]. The standard cancer treatment today consists
of surgery in combination with chemotherapy or radiothe-
rapy that induce DNA damage. Cancer cells that are rapidly
dividing are more sensitive to the DNA damage than normal
cells and defects in their DNA repair mechanisms also make
themmore vulnerable to acquiring toomuchDNAdamage and
entering apoptosis. The standard chemotherapeutic agents
are divided into three groups depending on their mechanism
of action; drugs inducing covalent crosslinks between DNA
bases (cisplatin, carboplatin), drugs attaching alkyl groups to
bases (methylmethanesulphonate (MMS), temoxolomide) and
drugs causing DSBs by trapping topoisomerase I or II (camp-
tothecin, etoposide, DR) [9,10]. Depending on the mutation
pattern in the DNA damage repair pathways (DDR) in each
tumour they are differently sensitive to the chemotherapeu-
tic agents. Tumours with defects in NER are, for example
more sensitive to cisplatin, reﬂecting their reduced capacity
to repair crosslinks [11].
The DDR defects offer an opportunity for more targeted
therapies. By inhibiting anadditional pathway in a cancerwith
pre-existing DNA repair defects a synergistic lethal effect is
created, exempliﬁed by for instance PARP inhibitors [12]. In
normal cells, the effects of PARP inhibition can be buffered
by the compensatory pathway HRR, but in BRCA mutants the
DSBs are left unpaired and can cause cell death [13,14]. Sev-
eral PARP inhibitors are now in Phase I and Phase II clinical
studies as well as other DDR inhibitors such as inhibitors of
CHK1 and APE1 [9,10]. The sensitivity to PARP inhibition is
more dependent on the BRCA genotype than the tissue ori-
gin, which is shown by their effectiveness in different BRCA
deﬁcient cancers such as breast, ovarian and prostate can-
cer [15,16]. This opens up a new concept of cancer research
where patients are selected for therapy based on their DDR
landscape rather than the tissue of origin. However, the exact
cancer killing mechanism of PARP inhibitors [17] as well as
many of the conventional cancer drugs is poorly understood
[18] and the design of optimal treatment regimes for cancer
patients would beneﬁt from extending our knowledge in this
area.
In this study, the aim was to investigate the response of
breast cancer cells to treatment with two different types of
chemotherapeutic drugs, the alkylation agent MMS [19] and
the topoisomerase II inhibitor, doxorubicin (DR) [18]. To this
end, the two breast cancer cell lines MCF-7 and MDA-MB-
231 were used that have differing chemo-sensitivities [20]. We
present a shotgun proteomic analysis together with an SRM
analysis of the main DNA repair pathways to investigate the
feasibility of developing a method for predicting or following
cellular responses to different DNA damage treatments.
2. Materials and methods
2.1. Materials
Acrylamide, urea, Tris, magnesium acetate, DTT, iodoac-
etamide and methyl methanesulphonate were from
Sigma–Aldrich (Stockholm, Sweden). Sequencing-grade
modiﬁed trypsin was purchased from Pierce (SDS diagnostics,
Falkenberg, Sweden). The Micro-Lowry Protein Assay Kit was
from Sigma Diagnostics (Stockholm, Sweden). The WST-1
Cell Proliferation Reagent was from Roche Diagnostics (Basel,
Switzerland) and the OxiSelect Comet Assay Kit was from Cell
BioLabs (San Diego, CA, USA). All HPLC solvents were from
Fluka (Sigma–Aldrich, Stockholm, Sweden). Doxorubicin was
from Meda (Solna, Sweden).
2.2. Cell culture and viability
The human breast cancer cell lines MDA-MB-231 and MCF-
7 were cultured in RPMI-1640 supplemented with 10% foetal
bovine serum (FBS) and 1% l-glutamine (Invitrogen, Carlsbad,
CA) and 10g/mL of insulin was added to the MCF-7 cell line.
The cells were maintained as monolayer cultures at 37 ◦C in
a humidiﬁed atmosphere at 5% CO2. The cell cultures were
exposed to MMS and DR for the various times and concen-
trations indicated. Cell viability was measured in duplicate by
Trypan blue exclusion after 1, 6 and 24h of treatment with
DR or MMS. Cells excluding Trypan blue dye were counted as
viable in Cell Countess.
2.3. COMET assay for DNA damage assessment
The amount of DNA damage was assessed with OxiSelect
Comet Assay Kit following the manufacturer’s protocol for
alkaline electrophoresis. Brieﬂy, cells were grown in 6-well
plates and treated with the indicated concentrations of DR
(2.5 and 25g/mL) or MMS (4 and 20g/mL). After 1 and 24h
of exposure, cells were trypsinised and washed, then resus-
pended in PBS and then mixed with agarose at 37 ◦C in a
1:10 ratio. The suspension was immediately transferred to the
COMETslide and incubated for 15minat 4 ◦C in thedark. Slides
were immersed in lysis buffer for 60min at 4 ◦C in the dark and
subsequently incubated in alkaline solution for 30min at 4 ◦C
in the dark. Electrophoresis was performed at 15V for 30min
and the slides were then washed with deionized water and
dried with ethanol before staining 15min with Vista Green.
COMETS were observed by ﬂuorescent microscopy (Nikon)
with 20× magniﬁcation and the images were analysed using
the COMET Score software.
2.4. Nuclear extraction
Cells were cultured as described above and treated with MMS
or DR. After 1 or 24h approximately 10 million cells were
washed twice with PBS and then resuspended in a hypo-
tonic homogenisation buffer (10mM HEPES pH 7.9, 10mM KCl,
1.5mM MgCl2, 0.5mM DTT, Complete Mini EDTA-free protease
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inhibitor). The MDA-MB-231 cells were incubated on ice for
15min while the MCF-7 cells were kept in 5mM HEPES pH 7.9,
5mM KCl, 0.75mM MgCl2, 0.25mM DTT, Complete Mini EDTA-
free protease inhibitor) for 20min on ice. The cells were then
disrupted using 20–40 strokes with a tight pestle in a 7mL
Dounce homogeniser until 90% of the cells were broken as
determined bymicroscopy. Subsequently, nuclei were pelleted
and stored in the freezer.
2.5. Separation of chromatin-associated and
nucleoplasm fractions
Nuclear pellets were thawed on ice and washed once with
ice-cold PBS and once with extraction buffer (15mM Tris–HCl
pH 7.4, 1mM EDTA, 400mM MgCl2, 10% glycerol, 10mM -
mercaptoethanol) before resuspension in 500L extraction
buffer and incubation for 1h on ice. Samples were then cen-
trifuged for 30min at 16,000× g and the supernatant was
diluted in hypotonic buffer (10mMTris–HCl pH 7.4, 10mMKCl,
1.5mM MgCl2, 10mM -mercaptoethanol) and saved as the
nucleoplasm fraction. Subsequently, pellets were washed and
resuspended in micrococcal nuclease buffer (20mM Tris–HCl,
10mM KCl, 2mM MgCl2, 1mM CaCl2, 300mM sucrose, pro-
tease inhibitor cocktail). Six units of S7 nuclease were added
and incubated with the samples for 30min on ice with mixing
every 4min. The nuclease was inactivated by the addition of
10L 0.5M EDTA and the samples were centrifuged for 3min
at 1500× g. The supernatant was diluted in hypotonic buffer
and saved as chromatin-associated fraction.
Nucleoplasm and chromatin-associated fractions were
precipitated by adding DOC to a concentration of 0.08% (w/v)
and incubating 30min on ice, followed by an addition of TCA
to a concentration of 2.5% (w/v) and 20min incubation on ice.
The precipitated proteins were collected by centrifugation at
3500× g for 30min.
2.6. Protein separation and digestion
The protein samples were mixed with sample buffer (0.05M
Tris–Cl, 0.05M SDS, 5% v/v glycerol, 0.1% DTT) and heated at
98 ◦C for 90 s before separation on a 12.5% SDS–PAGE gel with
a 4% stacking gel at 25 ◦C. Eighty micrograms of protein were
loaded per lane and the gel was run with 25amp/gel until
the bromophenol blue dye front had run off the base of the
gel. The gel was stained using Gel Code Blue Stain Reagent
(Pierce). Each of the lanes was cut into 10 slices that were
then destained in 50% acetonitrile and 25mM NH4HCO3. The
gel slices were reduced with 10mM DTT in 100mM NH4HCO3
at 56 ◦C for 1h. Alkylation was performed by adding 55mM
iodoacetamide acid in 100mM NH4HCO3 and incubating for
45min at RT in the dark. The slices were then washed once
with 100mM NH4HCO3 and several times using ACN. Trypsin
(25L of 12.5g/mL trypsin in 50mM NH4HCO3) was added to
the dehydrated gel slices. The samples were left for 30min
at 4 ◦C prior to incubation at 37 ◦C overnight. The peptides
were extracted from the gel by adding 5% TFA in 75% ACN
and incubating at RT for 30min. This was repeated once and
the two extractions were pooled. Subsequently, the volume
was reduced using a Speed vac and the samples were then
dissolved in 10L 0.1% formic acid. The 10 fractions were
subsequently analysed by RP-HPLC–MS/MS. Samples were run
in biological triplicate and technical duplicate.
2.7. LC–MS/MS analysis
The fractions were separated and analysed on an Eksigent 2D
NanoLC system (Eksigent Technologies, Dublin, CA, USA) cou-
pled to an LTQ OrbitrapXL (ThermoFisher, Bremen, Germany).
Peptides were loaded with a constant ﬂow of 10mL/min onto
a pre-column (Zorbax 300SB-C18 5mm×0.3mm, 5mm, Agi-
lent Technologies, Wilmington, DE, USA) and subsequently
separated on a RP-LC analytical column (Zorbax 300SB-C18
150m×75m, 3.5mm) at a ﬂow rate of 400nL/min using
a standard nanospray interface from Thermo. The peptides
were eluted with a 60min linear gradient of 3–35% ACN (0.1%
FA) followed by a 3min linear gradient from 35 to 90% ACN
(0.1% FA). The ion trap loadingwas set to 30,000with anMS/MS
threshold of 500 counts. The seven most intense ions were
selected for fragmentation with the dynamic exclusion dura-
tion of 2min.
2.8. Data analysis
Raw data ﬁles were imported in proﬁle mode into Progenesis
LC-MS version 3.1 (Nonlinear Dynamics, Newcastle, UK) and
aligned automatically. Visual inspection showed that man-
ual adjustment was not necessary. All peptide features with
MS/MS data were selected for the quantitation and identiﬁca-
tion. Searches were done against the human part of SwissProt
2011-08-17 with separate isoform entries and concatenated
with a reverse sequence database of equal size, totalling 71,324
entries, using Mascot version 2.3. The mass tolerance was set
to 3ppm for parent ions and 0.6Da for fragment ions and one
missed protease cleavage was allowed. Cys carbamidomethy-
lation was set as ﬁxed modiﬁcation, and Met oxidation as
variable. The FDR was set to <0.01.
2.9. Pathway analysis
Pathway analysis was carried out in MetacoreTM (version 6.13
fromThomsonReuters, NewYork, USA) using bothdifferential
pathway enrichment and experimental comparison modes. A
threshold of 1.2 up or down-fold regulation with an FDR ﬁlter
of 0.05 was implemented.
2.10. Speciﬁc reaction monitoring
2.10.1. Sample preparation
The nucleoplasm and chromatin-associated protein extracts
from each treatment were mixed and samples were run on
an SDS–PAGE as previously described. Each sample was cut
in three slices and reduced, alkylated and digested as previ-
ously described. Extracted peptides from the three slices were
pooled together, sample volume was reduced in a Speedvac
and the peptides were resuspended in 30L of 0.1% FA.
2.10.2. Design of SRM assay
SRM assays for 81 proteins using synthetic peptides. The syn-
thetic peptides (JPT peptides, Berlin, Germany) were mixed
and diluted in 5% ACN, 0.1% FA to 50pmol/L. The peptide
mixture was analysed on a TSQ Quantum Vantage equipped
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Fig. 1 – Viability of MDA-MB-231 and MCF-7 cells treated with DR or MMS, each at two different concentrations. The viability
is calculated as a ratio of the mean compared to the mean of the control cells. (A) DR-treated MDA-MB-231 cells. (B)
DR-treated MCF-7 cells. (C) MMS-treated MDA-MB-231 cells. (D) MMS-treated MCF-7 cells.
with a nanoelectrospray ion source (both from Thermo-Fisher
Scientiﬁc, Waltham, MA). Chromatographic peptide separa-
tion was performed on an Eksigent NanoLC 1D plus LC system
(Eksigent Technologies, Dublin, CA). Peptides were eluted by
a linear gradient of 5–60% ACN in 0.1% FA over 60min. The
dwell time was set to 10ms and the scan width to 0.01m/z.
A scheduled SRM transition list (Supplementary Table S1) was
created by running the synthetic peptides in a 1:1mixturewith
the samples from the treated cell lines. Samples were run in
biological duplicates.
Supplementary material related to this article can
be found, in the online version, at doi:10.1016/j.euprot.
2015.05.002.
2.10.3. SRM data analysis
The SRM data was analysed using the Anubis software
package version 1.2.1 [21]. The reference library was created
from the runs of synthetic peptides. The q-value cut-off was
set to 0.05; the null distribution to 100 and a limit of 6 tran-
sitions was used. Peak areas were normalised by total ion
current of a duplicate run inMS-onlymode. Protein intensities
were obtained by averaging intensities from all peptides from
the protein in question.
3. Results
In this study, we describe the proteomic response in a shot-
gun type study of two breast cancer cell lines to treatment
withDR (double stranded breaks) orMMS (alkylation) and then
focus onapathway centric analysis of theDNArepair response
based on SRM data.
3.1. Cell viability after DR or MMS treatment
The inﬂuence of DR and MMS on the viability of breast cancer
cells was evaluated after 1, 6 and 24h of treatment by Trypan
blue counting. The percentage of viable cells compared to the
control was calculated and is shown in Fig. 1. Both drugs have
after 24h of treatment a cytostatic effect on the two cell lines,
with the exception of the lower concentration of DR in the
MDA-MB-231, which shows a contrary response. In general,
the MDA-MB-231 cell line shows a higher resistance to both of
the drugs as compared to MCF-7, with approximately 60% via-
bility compared to approximately 30% after 24h of treatment.
3.2. DNA damage assessment
Since both of the two drugs (DR and MMS) act through the
induction of DNA damage, we assessed the amount of DNA
breaks in the cells using the COMET assay [22] as shown in
Table 1. The percentage of DNA in the COMET tails is propor-
tional to the amount of DNA breaks in the cells. A substantial
amount of DNA damage can be detected already after 1h in
the MDA-MB-231 cell line, even though there is no effect on
the cell viability. After 24h of exposure to DR, the amount of
DNA damage is lower compared to 1-h exposure, indicating
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Table 1 – DR- and MMS-induced DNA damage in
MDA-MB-231 and MCF-7 measured by the comet assay.
%DNA was calculated as a mean± standard deviation
(n=30).
Cell line Drug Time
(h)
Dose %DNA in
tail±SD
MDA-MB-231
Control
1
None 6.4±3.9
DR
Low 22.3±10.6
High 31.5±7.1
MMS
Low 5.1±2.9
High 17.2±6.7
Control
24
None 7.8±6.4
DR
Low 17.1±10.3
High 14.2±15.6
MMS
Low 29.1±14.4
High 16.4±10.5
MCF-7
Control
1
None 3.1±3.3
DR
Low 8.9±6.5
High 27.8±10.3
MMS
Low 3.8±4.0
High n/aa
Control
24
None 15.2±15.1
DR
Low 51.5±16.1
High 43.7±14.9
MMS
Low 21.1±14.6
High 48.3±20.3
a Missing value since the cells were too large to measure using this
method. The low and high concentrations of DR correspond to
2.5 and 25g/mL, respectively, and for MMS to 4 and 20g/mL,
respectively.
that the DNA damage machinery is efﬁciently repairing the
double-strand breaks. The amount of strand breaks in the cells
after 24h of drug exposure is much higher in the MCF-7 cell
line (44 and 52%) than in the MDA-MB-231 cells (14 and 17%).
3.3. Label-free analysis of protein expression changes
In order to study the proteomic response in the breast cancer
cell lines after drug treatment, the same concentrations of DR
and MMS as for the viability assay were used except for the
DR concentration that was 10-fold higher for COMET assay.
Cells were exposed to the drugs for either 1 or 24h and the
nucleoplasmand chromatin associated nuclear fractionswere
analysed by HPLC–MS/MS using label-free quantiﬁcation. The
MS runswere alignedand featuresweredetected in Progenesis
LC–MS software. From those features, a total of 8618 pro-
teins were identiﬁed (Table 2) and 2752 were quantiﬁed. Those
Fig. 2 – Venn diagram of the signiﬁcantly differentially
regulated proteins after MMS-treatment of MDA-MB-231
and MCF-7 cells.
proteins were representing a diverse set of pathways. Only
48% of the quantiﬁed proteins were shared between both the
cell lines. Among the top 10 statistically signiﬁcant pathway
maps in MetaCore for both cell lines were cell cycle processes,
apoptosis, cytoskeleton remodelling and translational events.
The number of proteins that were differentially regu-
lated with DR or MMS treatment was assessed by Student’s
t-test. More proteins were signiﬁcantly regulated after
MMS-treatment than after DR-treatment (Table 2). No pro-
teins that were signiﬁcantly regulated (p-value<0.05) after
both MMS-treatment and DR-treatment were shared between
the cell lines. Only seven differentially regulated proteinswere
shared between both cell lines as a result of MMS treatment,
including aspartate aminotransferase, epiplakin, myosin-4,
proteasome subunit alpha type-2, 60S ribosomal proteins and
FACT complex subunit SP16 (Fig. 2).
There are substantial response differences between the
cell lines and treatments. At 24h MDA-MB-231 cells show
a large up-regulation of oxidative phosphorylation whereas
MMS treatment causes down regulation and up-regulation of
cytokeratin remodelling andDNAdamage checkpoints.MCF-7
does not show these effects and is down regulating cell adhe-
sion via integrins and down regulation of tetraspanins like
CD151 and CD82 that can act as migration suppressors. How-
ever differential pathway analysis does not show signiﬁcant
differences in DNA repair response although there is overall
good coverage of the pathways, there is little overlap between
the cell lines and treatments.
Table 2 – Summary of all proteins found and proteins differentially regulated following treatment with DR or MMS.
MCF-7
chromatin
MCF-7
nucleoplasm
MDA-MB-231
chromatin
MDA-MB-231
nucleoplasm
Total
All proteins identiﬁed 4095 4844 4488 3959 8618
All proteins quantiﬁed 1352 1415 1377 1210 2752
DNA repair proteins quantiﬁeda 40 78 39 68 104
DR MMS DR MMS DR MMS DR MMS
All regulated proteins (p<0.2) 216 376 167 224 187 230 111 153
All regulated proteins (p<0.05) 25 126 23 53 37 56 18 36
a DNA repair proteins, as deﬁned by annotations in Uniprot.
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Table 3 – Pathway coverage of the DNA repair pathways. Pathways are those deﬁned by REACTOME and the pathway
coverage is calculated from the number of quantiﬁed proteins from both breast cancer cell lines.
Pathway name Proteins in
pathway
Proteins in
dataset
% Pathway
coverage
Nucleotide excision repair 49 27 55
Double-strand break repair 20 10 50
DNA repair 108 43 39
DNA damage reversal 3 1 33
Base excision repair 19 6 31
Telomere maintenance 32 9 28
Fanconi anaemia pathway 25 5 20
3.4. DNA repair pathway analysis of shotgun data
The results from the viability studies and the COMET assay
demonstrate a higher resistance to DR and MMS for the
MDA-MB-231 cell line, which is indicative of a more efﬁcient
DNA repair system. The drugs were chosen to typify two dif-
ferent kinds of DNA damage, MMS being an alkylating reagent
that introduces amethyl group primarily onN7-deoxyguanine
and DR that inhibits topoisomerase II enzyme and thereby
stalls the replication fork. Consequently, an up-regulation of
different pathways in the DNA damage response depending
on the type of damage induced was expected. However, in our
label-free shotgun experiment we identify many DNA repair
proteins that are responding, covering all of the main DNA
repair pathways (Table 3). The values are given in Supplemen-
tary Table S2. Most proteins are identiﬁed in the nucleotide
excision repair, double-strand break repair and base excision
repair. When looking at the total intensities of the proteins
found in the different pathways an up-regulation of those
pathways and the DNA damage checkpoint proteins are seen
for the MDA-MB-231 cell line, and to a lesser extent for
the MCF-7 cell line (Table 4). It can also be seen that the
intensity of theDNA repair proteins in theHRpathway goes up
for DR-treated MDA cells, supporting the COMET assay ﬁnd-
ings that MDA appears to be able to repair the double-strand
breaks.
Supplementary material related to this article can
be found, in the online version, at doi:10.1016/j.euprot.
2015.05.002.
3.5. DNA repair pathway analysis of SRM data
The result from the SRM analysis targeting of 75 DNA repair
enzymes covering all the main pathways is much richer. A
pathway-centric comparison of the regulation of each DNA
repair pathway as a whole is given in Fig. 3 for MDA-MB-231
cells responding to MMS and DR and in Fig. 4 for the response
of MCF-7 cells. The data for the individual proteins is given
in Supplementary Table S3. The MDA-MB-231 cells shows the
strongest response overall. Thirteen BER and 14 DDS enzymes
are seen to be up-regulated in an almost identical manner at
both DR treatment time and dosage points in line with the
Table 4 – DNA repair pathway intensities for MDA-MB-231 and MCF-7. Pathway intensity is calculated as the average
between the treatments with DR and MMS of the sum of the normalised intensities from Progenesis for all the proteins
quantiﬁed in each pathway. DNA repair pathway proteins are those deﬁned by Repairtoire. DDS, DNA damage signalling;
BER, base excision repair; NER, nucleotide excision repair; MRR, mismatch repair; HRR, homologous recombination
repair; NHEJ, non-homologous recombination repair.
DRR BER NER MRR HRR NHEJ
MCF-7 chromatin fraction
Proteins found 2 3 4 0 0 2
Control 733,752 358,075 487,067 – – 124,834
DR-treated 623,224 273,464 477,280 – – 152,819
MMS-treated 868,029 503,711 546,890 – – 199,650
MCF-7 nucleoplasm fraction
Proteins found 6 7 8 4 4 3
Control 185,331 1,296,803 754,281 52,973 808,021 972,581
DR-treated 174,031 1,313,898 607,942 72,405 1,000,469 1,391,589
MMS-treated 166,908 1,284,484 613,821 38,664 462,671 783,200
MDA-MB-231 chromatin fraction
Proteins found 1 2 4 1 1 2
Control 256 340,752 243,268 128,868 128,868 647,357
DR-treated 9085 469,826 271,032 83,370 83,370 716,597
MMS-treated 19,067 596,883 213,906 67,154 67,154 1,044,625
MDA-MB-231 nucleoplasm fraction
Proteins found 7 6 9 4 3 4
Control 1,644,246 10,117,828 1,155,448 13,045,216 200,593 10,796,633
DR-treated 2,319,296 8,640,002 2,394,286 2,505,779 391,986 11,088,164
MMS-treated 1,821,684 7,405,693 1,613,818 4,978,137 224,691 9,257,219
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Fig. 3 – Pathway-centric comparison of DNA repair pathway responses by SRM of selected DNA repair proteins in
MDA-MB-231 (same as for MCF-7). (A) Response to methyl methanesulphonate. (B) Response to doxorubicin. The response
values are log ratios of the SRM response averaged over all peptides used for a protein and then over all proteins assayed in
the respective pathway.
viability results shown in Fig. 1. All 16 NER enzymes are also
up regulated in a dose independent manner, as are the NHEJ
and MMR enzymes. Overall it is clear that the response to DR
is found in all pathways in a time dependent fashion. The
effect of MMS on the MDA-MB-231 cell line is much more vari-
able with a clear time dependent response for BER, NER, HRR
and DDS but with a weak dosage effect. The overall response
is weaker and is reﬂected in both the viability and COMET
responses.
Supplementary material related to this article can
be found, in the online version, at doi:10.1016/j.euprot.
2015.05.002.
The DR response of MCF-7 cells is rather heterogeneous
with only ﬁve BER enzymes showing up-regulation at 1h and
all pathways showing down regulation at 24h. The magnitude
of the response is dose dependent at 1h but all are down at
24h at high dose. There is virtually no response from the DDS,
NERandNHEJ pathways at either timeordosagewhereasMMR
Fig. 4 – Pathway-centric comparison of DNA repair pathway responses by SRM of selected DNA repair proteins in MCF-7
cells. (A) Response to methyl methanesulphonate. (B) Response to doxorubicin.
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shows an initial strong response followed by a large decrease.
The response to MMS is also highly heterogeneous and gen-
erally rather weak. All the observations are in line with the
greater sensitivity of the MCF-7 line to DNA damage as com-
pared to MDA-MB-231.
4. Discussion
Defects in DNA repair systems are common in different types
of cancers and may contribute to tumour development and
therapy resistance. Aberrant DNA damage response has been
correlated to lower survival rates for breast cancer patients
[23] and it has been proposed that response to chemother-
apy can be predicted by analysing DNA damage repair protein
expression by immunohistochemistry [24]. We have investi-
gated the response of two breast cancer cell lines, MCF-7 and
MDA-MB-231, to chemotherapeutics. MCF-7 is a luminal-type,
ER positive cell line while MDA-MB-231 is basal-like, ER nega-
tive and p53 is mutated. Cancer cells expressing only mutated
p53 are associated with a decreased sensitivity to DNA dam-
age inducing cancer therapies [25]. Higher doses of etoposide,
cisplatin and nitrogen mustard were reported to be required
for inhibition of cell survival in p53 mutant cells as compared
to wild-type cells [26]. p53 has more speciﬁcally been shown
to be important for the sensitivity to the drug epirubicin [27],
which is derived from DR and has a similar mechanism of
action [28]. The differences in the molecular subtype of the
two breast cancer cell lines in our study can thus explain
the higher viability and lower amount of DNA damage after
drug treatment in MDA-MB-231 compared to MCF-7 (Fig. 1
and Table 1). Our results are in agreement with previous ﬁnd-
ings that MDA-MB-231 is more resistant than MCF-7 to DR and
retain a higher viability after drug exposure. The heterogene-
ity in the drug response of the cell lines is also reﬂected in
the low number of differentially expressed proteins in com-
mon between the cell lines. However, among the differentially
expressed proteins in each cell line, several were reported in a
previous study identifying 11 biomarkers of apoptosis follow-
ing chemotherapy [29] (KRT18, EIF5 and several ribosome 60S
proteins).
In contrast, at the proteomic level, the general pathways
identiﬁed in our datasets were quite similar between the
cell lines. A diverse set of pathways was identiﬁed, including
processes involved in the cell cycle, apoptosis, cytoskeleton
remodelling and translation.
To explain the decreased sensitivity at a pathway level
we focused on the DNA repair processes by SRM since the
drugs are known to induce different kinds of DNA damage.
DR is acting by inhibiting topoisomerase II and stalling the
replication fork with strand breaks as a consequence. There
are reports that the drug concentration used can inﬂuence
the mode of action of this drug and Gewirtz [18] reported
protein-associated strand breaks (presumably from inhibi-
tion of topoisomerase II) at lower drug concentrations while
non-protein-associated DNA strand cleavage was found as a
consequence of free radicals induced at higher concentra-
tions. In our experiment, topoisomerase II was expressed at
lower concentration following DR treatment than MMS treat-
ment supporting the topoisomerase II mode of action of DR.
The fact that we only identiﬁed topoisomerase II in the MCF-7
cell line but not in MDA-MB-231 is in line with the hypoth-
esis that DR-resistant cells have less of this protein. MMS
is an alkylating agent adding a methyl group primarily on
N7-deoxyguanine and should therefore trigger the base exci-
sion pathway for repair [19]. MMS has been reported as a
potent inducer of BER in mouse [30]. Thus, we were expect-
ing an increase in the DNA repair proteins associated with BER
after MMS treatment. We observed, however, an up-regulation
of proteins in several of the DNA damage pathways.
5. Conclusions
The DNA repair pathway response after chemotherapeutic
treatment of breast cancer cell lines is not clearly indicating
the type of damage induced/the drug used, indicating that a
highdegree of crosstalk between thepathways occurs. In order
to understand the mechanisms of drug sensitivity and resis-
tance, a deeper knowledge of the protein regulation in DNA
repair pathways is desirable. A shotgun approach yielded a
broad overview of the cellular processes taking place but to
a large degree masked the changes in DNA repair pathway
level changesoccurring in response toDNAdamage. SRManal-
ysis could rectify this shortcoming. When overlap occurred
between shotgun and targeted SRM therewas good agreement
on the protein level but on the peptide level someoutlierswere
observed possible due to isoforms or post-translational modi-
ﬁcations. We believe that these assays that we have developed
cover enough of the DNA repair response that a prospec-
tive proﬁling of patients, before, during and after neoadjuvant
chemo- or radiotherapy may be a useful tool to help quantify
treatment response at early times before tumour shrinkage is
visible.
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